Nohla and UC Davis Ink Manufacturing Deal for Off-the-Shelf Donor Stem Cell Therapy – Genetic Engineering & Biotechnology News

Nohla Therapeutics is tapping the University of California, Davis (UC Davis) for its expertise in cell therapy GMP and manufacturing so that it can scale up clinical trials manufacture of NLA101, Nohla's Phase IIb-stage off-the-shelf universal donor stem and progenitor cell therapy for hematologic cancers. The firm will also work with UC Davis to further optimize the NLA101 manufacturing process, with a view to future commercial production.

Under terms of the collaboration and manufacturing agreement, UC Davis will carry out manufacturing and quality control testing of NLA101 at the UC Davis Institute of Regenerative Cures (IRC) cGMP Cell Therapy Manufacturing Facility in Sacramento, CA. Nohla has sublicensed office and laboratory space at the Oak Park Research Center next to the IRC, which will act as a warehouse and distribution center for supplying the IRC with raw materials and for storing NLA101 for distribution to the clinical trials sites. The collaboration will enable the production of enough NLA101 to supply clinical trials evaluating NLA101 in hematopoietic cell transplant and for treating chemotherapy-induced neutropenia.

This collaboration allows Nohla to capitalize on the expertise at UC Davis to scale manufacturing for NLA101 and increase our ability to supply product for multiple clinical trials, commented Kathleen Fanning, president and CEO at Nohla.

Lars Berglund, M.D., Ph.D., associate vice chancellor for biomedical research and vice dean for research at UC Davis School of Medicine, added, We are particularly excited to partner with Nohla for the development of this groundbreaking technology as it demonstrates our commitment to work with innovative companies developing lifesaving therapies.

Nohla was established in 2015 to exploit technology developed at the Fred Hutchinson Cancer Research Center, which enables the Notch-mediated ex vivo expansion and directed differentiation of cord blood stem and progenitor cells into off-the-shelf universal donor cell therapies that can be used on demand without human leukocyte antigen (HLA) matching in recipients.

The lead product NLA101 has been evaluated in more than 100 patients at high risk of severe infection and other complications after chemotherapy or cord blood transplantation. A Phase IIb study is ongoing in patients undergoing myeloablative cord blood transplant for leukemia and other blood cancers. Nohla is also planning to start a Phase II study in patients undergoing high-dose chemotherapy for acute myelogenous leukemia (AML).

In November 2016, Nohla raised $43.5 million in a Series A financing round, taking total investment in the company to $64.5 million.

Continued here:
Nohla and UC Davis Ink Manufacturing Deal for Off-the-Shelf Donor Stem Cell Therapy - Genetic Engineering & Biotechnology News

Health Check: Stem cell treatment for ALS – Turn to 10

by BARBARA MORSE SILVA, NBC 10 NEWS

A Rhode Island man is waging a fight for his life.

Arthur Saran, 42 was diagnosed with ALS a year and a half ago.

"You really become a prisoner of your own body with your mind not getting affected at all," said Saran through his eye-controlled computer, which speaks for him.

His girlfriend, Chelsey Renehan, too, has become very vocal about his journey, which began in August 2015.

"He sent me the video while he was at the gym of his leg shaking," said Renehan.

Then Saran started noticing his balance was off and his speech was becoming slurred.

"When I was diagnosed with ALS, we didn't just accept it and wait to die because most neurologists say there really is nothing they can do," said Saran, via his computer.

The couple, who are raising an active 7-month-old, Arthur Jr., decided that wasn't good enough. They learned about stem cell treatments. But finding a trial to sign up for was quite the job. This Rhode Island couple went to Massachusetts and Connecticut.

"And then finally, the doctor in Connecticut had connected with another doctor who had found success with a few patients up in Canada to doing stem cells," said Renehan.

Since last October, every six weeks, Saran has gone in for stem cell treatments. He's had a total of four.

"Huge difference, said Renehan.

"My core got stronger which helps sitting up," said Saran.

"He's able to swallow more easily," added Renehan.

"I can also flex my right arm and move my left thumb which both never moved, noted Saran via computer. "The best improvement is now I can go to the bathroom easily."

And this couple feels with continued treatments, they will see more improvements.

But they also know the associated costs with all the treatments which add up to thousands of dollars a month. And they want to make sure others have the access to treatments, like Saran has. So they're starting a foundation.

"The focus of the Saran Stem Cell Foundation is helping people with the associated costs of the treatments and of course, connecting them to actually getting the stem cell treatments," said Renehan.

"I truly believe that I was given this disease for a reason," said Saran.

Saran believing his diagnosis, his journey is meant to help others.

They are in the process of getting this foundation off the ground. You can follow Saran's story on Facebook.

Go here to read the rest:
Health Check: Stem cell treatment for ALS - Turn to 10

Stem-cell therapy: The medicine of the future – Ynetnews

In one of the famous scenes of American animated sitcom Family Guy, which was aired on January 2008, the main character, Peter Griffin, is seen entering a stem cell research lab with half his body paralyzed, as a result of a stroke, and walking out completely healthy.

Growing a heart on a plate (PR photo)

Imagination plays an important role in dealing with stem cells. Theoretically, cells that, in a lab, can differentiate into any specialized cell present countless options of playing with the human bodyfrom treating any physical medical failure, through preparing a bank of human spare parts, to producing a new race of perfect human beings, completely flawless and immune. That is only in theory, however, at least at this stage. In practice, the possibilities inherent in stem cells are still imaginary, and using them for actual treatment is still very limited.

Torontos skyline is dotted with multi-story buildings, each with a series of elevators that fly visitors within second from the ground floor to the upper floors. The 35th floor of Eaton Centre, a shopping mall and office complex located near Dundas Squarewhich locals say is like Times Square, only a lot less impressiveoverlooks almost all parts of the Ontario provinces capital.

Using stem cells for the sake of humanity (Illustration photo: Shutterstock)

The most fascinating research has to do with cardiology. This is the field in which the ability to imagine a new era in the near future appears most palpable. Its difficult to overstate the complexity of the human heart, which is made up of different types of cells and tissues and is activated through a sequence of electrical pulses. Modern medicine has been unsuccessful so far in creating an industrial alternative for the heart, at least not one that allows a quality of life, while transplant surgery suffers from the risks of transplant rejection and a regular donor shortage. These limitations, in addition to the fact that heart diseases are very common and are one of the leading causes of death around the world, make cardiology a fertile ground for an industry of innovative medicine.

PR photo

One field in which this vision has already become a reality, at least partially, is lung therapy. Stem cell medicine holds a potential in terms of lungs suitable for transplantation, when it comes to improving of the chances that the new body wont reject the organ. The entire process, however, is complicated. Lung transplantation is only possible when the person who agreed to donate his organs in advance is declared brain dead, which makes it possible to harvest the organs before the entire body collapses, and these are pretty specific cases. In addition, in this group only 20 percent of the donated lungs are eventually transplantedas the procedure must be quick, and in most cases doctors dont have sufficient information about the lungs condition and the ability to prepare it for a transplantation which wont be rejected.

PR photo

In the stem-cell therapy labs in Toronto, the future is both present and absent. Most researchers refuse to fall into the press trap and talk about a vision for a better future in which every problem will be treated by injecting stem cells. And although the phrase growing a heart on a plate is occasionally heard, they make sure to clarify that such a situation is still far off. Nevertheless, no one will deny that stem-cell therapy is the medicine of the future.

The combination of medical and technological innovations may have brought humanity to the start of a new era, in which it will be possible to cure the body in an immensely more efficient way than in the past. But even these accomplishments highlight how little we know about the human body and how much more we need to learn and work in order to be able to unlock the full potential hiding deep within our cells.

(Translated and edited by Sandy Livak-Furmanski)

Go here to see the original:
Stem-cell therapy: The medicine of the future - Ynetnews

Interferon-beta producing stem cell-derived immune cell therapy on … – Science Daily


Science Daily
Interferon-beta producing stem cell-derived immune cell therapy on ...
Science Daily
Induced pluripotent stem (iPS) cell-derived myeloid cells (iPS-ML) that produce the anti-tumor protein interferon-beta (IFN-beta) have been produced and ...

and more »

See the original post:
Interferon-beta producing stem cell-derived immune cell therapy on ... - Science Daily

Stem Cell Treatment Cures Impotence in Some Prostate Cancer Surgery Patients – Newsmax

Stem cell treatment helped treat erectile dysfunction in some -- but not all -- prostate cancer surgery patients, a new study says.

It included 21 men who became impotent after surgery to remove their cancerous prostate. They received stem cell injections meant to restore damaged nerves. After a single stem cell injection, eight of the men regained sexual function and kept it for a year, NBC News reported.

The study was presented at a European Association of Urology meeting.

"What we have done establishes that this technique can lead to men recovering a spontaneous erection -- in other words, without the use of other medicines, injections, or implants," Dr. Martha Haahr of Odense University Hospital in Denmark, said.

The researchers plan to conduct a larger study.

"If it works in these men (who've had their prostate removed), it would also work in men with have been treated using chemotherapy and radiation," and may also help men with erectile dysfunction caused by aging, heart disease or diabetes, according to Haahr, NBC News reported.

"If it's as effective as we think, it could help many kinds of men," she said.

Read this article:
Stem Cell Treatment Cures Impotence in Some Prostate Cancer Surgery Patients - Newsmax

Stem cell transplants offer hope for sufferers of gut disorders – Medical Xpress

March 29, 2017 by Elisabeth Lopez Enteric neurosphere in mice. Credit: Wikimedia

After a baby is born, a souvenir of its months in the womb is usually not long to follow. Its first poo, or meconium, is a lump sum of everything the foetus has ingested for months; a dark sludge, compared by the insomniac readers of parenting forums to engine oil or tar.

That first stool is probably the ground zero for Dad jokes. But if it hasn't emerged after 48-72 hours, doctors know to start looking for Hirschsprung Disease. Although rare, affecting one in 5000 live births, Hirschsprung's effects can be debilitating and lifelong, including bowel obstructions, constipation, reflux and vomiting.

"The muscles in the gut wall of these babies are not doing their job, which is to push food through the intestines, because the gut nerves are missing. The milk accumulates, their bellies get distended and the effect is like blocking the end of a fire hose," says developmental neurobiologist Professor Heather Young, of the University of Melbourne.

Professor Young's lab is exploring the potential for stem cell transplants to treat Hirschsprung's Disease, and other disorders of the gut's nervous system. In a recently published article, the team extracted stem cells from healthy parts of the bowel, grew them in a dish (these tiny balls, called neurospheres, measure one fifth of a millimetre, requiring some very fine forceps), and transplanted them back into sections of the gut wall that are missing neurons in Hirschsprung disease.

Currently, the only treatment for Hirschsprung's is surgery, which, while lifesaving, is usually followed by complications and psychosocial issues from problems such as soiling.

"For kids with the most severe form of the disease, life is really tough. They're on a feeding tube and total parenteral (intravenous) nutrition for the rest of their lives," Professor Young says.

The research team, based at the University, the Florey Institute and Queen's University in Canada, is investigating what happens when the development of the gut nerves, or enteric nervous system, is derailed, causing disorders like Hirschsprung's. Often called the 'second brain', this extensive network of 500 million neurons (five times the number of neurons in the spinal cord) controls digestion and excretion.

Our gut neurons are responsible for gut motility, or peristalsis the muscular spasms that push food from the stomach, into the intestines and out through the anus. And researchers are now also exploring its influence on mood and behaviour, and links with conditions such as autism and even some forms of epilepsy. .

When things go well, the enteric nervous system rumbles away in the background, beyond conscious control or awareness (barring the odd tummy ache). But when things go awry, the effects can be devastating.

The gut odyssey

Like all epic stories, the story of the gut nervous system begins with a massive migration.

Gut neurons start life as stem cells located near the base of the developing brain. Making their way from the neural tube into the developing gut tube, they then colonise the entire gastrointestinal tract. Once there, many of them differentiate into nerve cells that make the muscles in the gut wall relax, while some differentiate into nerve cells that are responsible for contractions. Others, known as interneurons, are the middlemen that connect those movements into a rhythm.

"Think of the East coast of Australia as the gastrointestinal tract, with Cairns the oesophagus and Melbourne the . . .ahem . . .other end," explains Lincon Stamp, from Prof Young's laboratory.

"Imagine people migrating down the coast in their cars, all from top to bottom. Normally some make it all the way to Melbourne, with others stopping off to set up homes in cities along the way. However, sometimes the people destined for Melbourne run out of fuel and are stranded further up the coast.

"In Hirschsprung disease this is due to genetic defects some random, some inherited which cause the migrating cells to run out of fuel, leaving them stranded and the last part of the bowel unoccupied."

Most infants are diagnosed with Hirschsprung before they leave hospital, but if only a small region of the bowel is affected, the condition might not be picked up for weeks or months. Surgeons will often remove the affected section of bowel and reattach what's left.

"When neurons in your bowel are diseased or damaged, they're really challenging conditions for gastroenterologists to treat. There are currently no drug treatments," says Dr Stamp.

Gut motility disorders also strike later in life, but these ones tend to affect specific subpopulations of nerves much as Parkinson's disease affects a specific type of brain neuron. By contrast, childhood disorders are usually defined by a total absence of neurons in sections of the bowel or the entire organ.

One increasingly common adult condition is gastroparesis, which is associated with uncontrolled diabetes, Parkinson's disease, and MS. Another is achalasia, characterised by the loss of neurons that enable the sphincter to open and close the oesophagus. It mainly affects elderly people, and is a kind of mirror image to the popular complaint of gastrointestinal reflux, where stomach acid leaks out and up from the oesophagus. Only in achalasia, the oesophagus fails to open at all.

"They can't swallow solids they end up living on soup and liquids. They can choke because the sphincter is not opening," Professor Young says.

Completing the migration

The work by Lincon Stamp and his team on an animal model of Hirschsprung disease is essentially about completing that disrupted migratory journey of stem cells from the brain to the bowel.

"We've shown that they migrate and colonise a reasonably good area of the bowel after the transplant," says Dr Stamp.

"We've been able to transplant cells that survive four months, while another group in the UK has achieved 24 months."

The transplanted cells not only survive they look and behave like neurons.

"Stem cell therapy for a gut motility disorder requires neurons that don't just fire they have to connect with the muscle in the gut wall, to control the relaxation and contractions that move food through," Dr Stamp says.

A new technique called optogenetics enabled the team to confirm the transplanted neurons were behaving as they should. Optogenetics involves inserting light-sensitive proteins, derived from green algae and called opsins, into neurons. The opsins activate the neurons. The team recorded the results to check for signals from the muscles. (Before opsins came on the scene around 2008, neuroscientists could only use electrodes to control neurons).

One of the challenges for the Young lab is isolating gut stem cells in humans and gathering them in sufficient numbers for transplantation. One UK lab has developed technique to make this much easier via routine endoscopies, opening the way to future patient-derived stem cell treatments.

"While a stem cell therapy for humans with gut motility disorders is likely still years away, this study is an exciting leap forward in progress toward that goal," Dr Stamp said.

Explore further: A gut feeling about neural stem cells

More information: Lincon A. Stamp et al. Optogenetic Demonstration of Functional Innervation of Mouse Colon by Neurons Derived From Transplanted Neural Cells, Gastroenterology (2017). DOI: 10.1053/j.gastro.2017.01.005

Proper function of the digestive system requires coordinated contraction of the muscle in the wall of the intestinal tract, regulated by the enteric nervous system. Damage or loss of these neurons can result in intestinal ...

Researchers led by the Francis Crick Institute have developed a zebrafish model of a human disease - Hirschsprung disease - that enables them to study the disease's causes and consequences in living animals and will help ...

A study by scientists at Children's Hospital Los Angeles has shown that tissue-engineered colon derived from human cells is able to develop the many specialized nerves required for function, mimicking the neuronal population ...

Numerous human diseases, including inflammatory bowel disease, diabetes and autism spectrum disorders have been linked to abnormal gut microbial communities, or microbiomes, but an open question is whether these altered microbiomes ...

The enteric nervous system (ENS), the "little brain" that resides within the gut wall, governs motility, secretion, and blood flow in the human gastrointestinal tract. Failure of the ENS to develop normally leads to congenital ...

Genetic studies in humans, zebrafish and mice have revealed how two different types of genetic variations team up to cause a rare condition called Hirschsprung's disease. The findings add to an increasingly clear picture ...

A newly approved drug that is the first to reflect the current scientific understanding of multiple sclerosis (MS) is holding new hope for the hundreds of thousands Americans living with the disease.

With more than 130,000 victims nationwide, strokes are among the leading causes of death in the U.S. each year. According to the Centers for Disease Control (CDC), someone in the United States has a stroke every 40 seconds, ...

After a baby is born, a souvenir of its months in the womb is usually not long to follow. Its first poo, or meconium, is a lump sum of everything the foetus has ingested for months; a dark sludge, compared by the insomniac ...

Tech billionaire Elon Musk is announcing a new venture called Neuralink focused on linking brains to computers.

New research from scientists at the University of Sussex has taken a major step towards unlocking the secrets of hypnosis and gathering evidence that suggests that subjects aren't faking the effects of it.

Older adults who have been scammed by friends, relatives or strangers seem to behave just like elders who have avoided rip-offs. They are able to balance their checkbooks. They can remember and evaluate information. Their ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

View original post here:
Stem cell transplants offer hope for sufferers of gut disorders - Medical Xpress

Does the Catholic Church Oppose All Stem-Cell Research?

Important Questions

The Catholic Church is concerned with the protection of all innocent human life, as Pope Paul VI's landmark encyclical, Humanae vitae (1968), made clear. Scientific research is important, but it can never come at the expense of the weakest among us.

Stem cells are a special type of cell that can easily divide to create new cells; pluripotent stem cells, which are the subject of most research, can create new cells of various types. Over the last several years, scientists have been optimistic about the possibility of using stem cells to treat a wide range of diseases and other health problems, because stem cells could potentially regenerate damaged tissues and organs.

While news reports and political debates often use the term stem-cell research to discuss all scientific research involving stem cells, the truth is that there are a number of different types of stem cells that are being studied. For example, adult stem cells are often drawn from bone marrow, while umbilical-cord stem cells are taken from the blood that remains in the umbilical cord after birth.

Most recently, stem cells have been found in the amniotic fluid that surrounds a baby in the womb.

There is no controversy about research involving all of these types of stem cells. In fact, the Catholic Church has publicly supported adult and umbilical-cord stem-cell research, and Church leaders were among the first to applaud the discovery of amniotic stem cells and to call for further research.

The Church has consistently opposed research on embryonic stem cells, however. For several years now, many scientists have called for greater research on embryonic stem cells, because they believe that embryonic stem cells exhibit greater pluripotency (the ability to divide into different types of cells) than, say, adult stem cells.

The public debate around stem-cell research has focused entirely on embryonic stem-cell research (ESCR). The failure to distinguish between ESCR and other forms of stem-cell research has muddied the debate.

Despite all of the media attention that has been devoted to ESCR, not a single therapeutic use has been developed with embryonic stem cells. In fact, every use of embryonic stem cells in other tissue has led to the creation of tumors.

The greatest advances in stem-cell research so far have come through adult stem-cell research: Dozens of therapeutic uses have been developed and are currently in use. And the discovery of amniotic stem cells may well provide scientists with all the advantages that they had hoped to derive from ESCR, but without any of the moral objections.

On August 25, 2000, the Pontifical Academy for Life released a document entitled Declaration on the Production and the Scientific and Therapeutic Use of Human Embryonic Stem Cells, which summarizes the reasons why the Catholic Church opposes ESCR.

It doesnt matter whether scientific advances may be made through ESCR; the Church teaches that we can never do evil, even if good may come of it, and there is no way to obtain embryonic stem cells without destroying innocent human life.

Link:
Does the Catholic Church Oppose All Stem-Cell Research?

Using stem cells to create an endless supply of blood – CNN

"This technology gives us that particular dream, or at least it brings us a lot closer," said Klein.

To ramp up production, the UK researchers infected stem cells with cervical cancer genes. By inserting cancer genes from human papilloma virus (HPV) into bone marrow cells, Frayne and her colleagues were able to create the first adult red blood cells that could multiply an infinite number of times. These cells are referred to as "immortal."

As the red blood cells mature, they spit out the nucleus -- the core that houses their DNA -- giving the cells a signature round, dimpled shape. Frayne and her colleagues filtered those cells from the rest, so the final batch did not contain the active cancer genes.

Frayne said that a small number of these stem cells can be found in a simple blood draw, too; there's no need to do an invasive biopsy of the bone. Since her team completed the study last year, she said, they have already created two new immortal cell lines this way.

But his cells didn't eject the nucleus well enough, and fetal blood cells have too tight a grip on oxygen; they are less likely to drop off the oxygen where it needs to go. Eventually, though, he abandoned the research because "it's not really commercially viable."

Many others have attempted to create blood in the lab, using stem cells from umbilical cords and other sources. But these stem cells fizzle out and stop dividing at a certain point.

"It's almost like they desperately want to carry on differentiating" into mature cells, Frayne said.

Frayne said that the first human trials will begin in England later this year, though they will not be using the immortal cells from her new study. Making the new cells under industry standards, Frayne said, could take at least several more years.

But where Lanza really expects to see this technology is on the battlefield.

Lanza, who met with DARPA officials about his own blood cell research in the past, said that the military wants to use lab-grown blood "for patients who have massive blood loss, particularly in the battlefield, where a soldier is blown up by a bomb and there isn't time for blood typing."

"I think the goal ultimately is to put this on the back of a Humvee," he said.

That research, however, met the same obstacles other scientists faced in the past, Klein said.

"They were not able to make sufficient amounts blood at any kind of reasonable cost," said Klein, who also serves on the FDA Blood Products Advisory Committee. Though familiar with the DARPA research, he was not involved in evaluating its products.

"To make big huge vats of it would be outside of our ability in a research lab," she said. "We'd have to have company interest."

A hospital in the US might pay hundreds to thousands of dollars to purchase and test a unit of donated blood, and it may charge far more to transfuse it to patients. Producing a pint of blood using her method, Frayne said, would likely be several times more expensive than buying bags from blood donors in the UK.

But Frayne is optimistic that costs will come down. She hopes that lab-grown cells will be shown to last longer, and therefore doctors might need to use less blood less frequently. That's because stem cells can be collected while they're young, Frayne said, while human blood has cells of all different ages. Many donated blood cells die not long after transfusion.

That aside, Klein said that lowering the cost to $1,000 to $2,000 per unit of blood would make these cells worth the price for a small subset of patients who have rare blood types or need regular transfusions. For the typical hospital patient, however, it would probably not be very practical or cost-effective, he said.

But it is their willingness to invest money in the research, Klein said, that may have led to the British team's success where the US and other countries have faltered.

"They have put a great deal of financial muscle behind doing this on a national basis, which we simply haven't seen in the United States," he said, adding that perhaps there was an element of "healthy skepticism (in the US) that maybe it will never in our lifetime be practical."

"I don't share that skepticism," he said.

But what about the rogue red cell that slips through the filter with its cancer genes still intact? Lanza calls these cells "escapees."

"When you're dealing with such huge numbers of cells," said Lanza, "there may be a few of these cells that would slip in."

Frayne said that these cells are highly unlikely to cause any form of blood cancer. The cancer genes are only switched on by a certain antibiotic, and by the time the cells are collected, any remaining nuclei are no longer working. Before blood transfusion, radiation can also be used to destroy any leftover DNA without affecting normal cells, she said.

Still, Frayne said, "These are all really good points to be raising, and they need to be looked at."

But none of these concerns have slowed a deluge of requests to use her cells, Frayne said, though perhaps not from whom you'd expect. It's not blood banks hoping to capitalize on a new, if untested, method. In fact, it's other researchers who, until now, have not had an unlimited way to study diseases like malaria, which infect red blood cells. "That's where all my requests are coming from," she said.

Klein, Lanza and Frayne all said lab-grown blood cells are not meant to replace blood donors. To fill a national blood service, or even a single hospital, will require another major leap in the research.

"They're not going to put the Red Cross out of business," said Lanza. "Volunteer blood donations are always going to be the first line of defense -- but with this technology, you have a safety net."

See more here:
Using stem cells to create an endless supply of blood - CNN

Researchers turn urine into research tools – Science Daily


UCLA Newsroom
Researchers turn urine into research tools
Science Daily
One of the biggest challenges in studying Down syndrome is finding the right research model. Animals and established cell lines are limited in their ability to mimic human disease, and results don't always translate to patient populations. Stem cells ...
Pioneering stem cell gene therapy cures infants with bubble baby diseaseUCLA Newsroom
Stem-cell therapy: The medicine of the futureYnetnews
US Stem Cell Inc (OTCMKTS:USRM) Up Nearly 20% Recently After These Recent DevelopmentsStreet Register
Technology Networks -Yahoo Finance -University Herald
all 34 news articles »

Continue reading here:
Researchers turn urine into research tools - Science Daily

Animal Clinic of Council Bluffs and Glenwood Veterinary Clinic Offer Stem Cell Therapy for Pets – P&T Community

Animal Clinic of Council Bluffs and Glenwood Veterinary Clinic Offer Stem Cell Therapy for Pets
P&T Community
COUNCIL BLUFFS, Iowa, March 26, 2017 (GLOBE NEWSWIRE) -- MediVet stem cell therapy, offered at Animal Clinic of Council Bluffs and Glenwood Veterinary Clinic, provides pets and owners with a way to address health concerns in cats and dogs.

and more »

Read more from the original source:
Animal Clinic of Council Bluffs and Glenwood Veterinary Clinic Offer Stem Cell Therapy for Pets - P&T Community